Results 131 to 140 of about 1,103 (154)
Some of the next articles are maybe not open access.
Research Journal of Pharmacy and Technology
The objective of this research was to formulate and evaluate mucoadhesive in situ nasal gels as a novel delivery system for Bepotastine Besilate. Aiming to provide sustained drug release directly at the site of action, thereby reducing the need for ...
A. Prajapati +5 more
semanticscholar +2 more sources
The objective of this research was to formulate and evaluate mucoadhesive in situ nasal gels as a novel delivery system for Bepotastine Besilate. Aiming to provide sustained drug release directly at the site of action, thereby reducing the need for ...
A. Prajapati +5 more
semanticscholar +2 more sources
American Journal of Ophthalmology, 2010 To evaluate the effectiveness of bepotastine besilate ophthalmic solutions 1.0% and 1.5% compared with placebo at reducing ocular itching and conjunctival hyperemia in the conjunctival allergen challenge (CAC) model of allergic conjunctivitis.Prospective, double-masked, randomized, placebo-controlled, phase 3 CAC clinical trial.This multicenter trial ...
Mark B Abelson, Paul J Gomes
exaly +4 more sources
Bepotastine Besilate for the Treatment of Pruritus
Expert Opinion on Pharmacotherapy, 2013Bepotastine besilate 1.5% is a newly approved second-generation topical antihistamine indicated for the pruritus associated with allergic conjunctivitis. In Japan, the oral formulation is approved to manage pruritus associated with allergic rhinitis and urticaria.Bepotastine is a piperidine derivative that antagonizes H1 receptors with high selectivity.
Leonard Bielory
exaly +3 more sources
Indian Journal Of Applied Research, 2023
Allergies are the sixth most common kind of chronic disease since they impact more than 40% of the population. The incidence of allergic diseases has increased at an alarming rate over the course of the last ten years, [1] impacting individuals in every ...
Siddhi Mathur +2 more
semanticscholar +1 more source
Allergies are the sixth most common kind of chronic disease since they impact more than 40% of the population. The incidence of allergic diseases has increased at an alarming rate over the course of the last ten years, [1] impacting individuals in every ...
Siddhi Mathur +2 more
semanticscholar +1 more source
Bioequivalence Test of "Dong-a Bepotastine Besilate Tab" and "Twolion Tab"
Case Medical Research, 2019semanticscholar +2 more sources
Design and Evaluation of Ophthalmic Delivery of Bepotastine Besilate From Eye Drop
Pharmaceutical Methods, 2016 Introduction: The purpose of present study was to design and evaluate bepotastine besilate ophthalmic solution 1.5% to develop a stable formulation using buffering agent, tonicity modifier and preservative. Method: In this study the concentration of preservative and tonicity modifier concentration are adjusted in such a way so that the final ...
Sonali S. Askarkar, K. Gupta
semanticscholar +3 more sources
Pharmacokinetic Comparisons of Bepotastine Besilate and Bepotastine Salicylate in Healthy Subjects
Clinical Drug Investigation, 2013Bepotastine is a second-generation histamine H(1) receptor antagonist that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease. The aim of the present study was to compare the pharmacokinetics of two different bepotastine formulations [bepotastine besilate 10 mg (reference) and bepotastine salicylate 9.64 mg (test)],
Kyoung-Ah, Kim, Ji-Young, Park
openaire +2 more sources
Drug Development and Industrial Pharmacy, 2012
To develop a novel salt form of bepotastine with bioequivalent to the commericial bepostastine besilate, bepostastine salicylate was prepared and its physicochemical properties were investigated. Furthermore, the bepotastine salicylate-loaded tablet was prepared by the wet granulation method, and the dissolution and bioavailability in beagle dogs were ...
Kwan Hyung, Cho, Han-Gon, Choi
openaire +2 more sources
To develop a novel salt form of bepotastine with bioequivalent to the commericial bepostastine besilate, bepostastine salicylate was prepared and its physicochemical properties were investigated. Furthermore, the bepotastine salicylate-loaded tablet was prepared by the wet granulation method, and the dissolution and bioavailability in beagle dogs were ...
Kwan Hyung, Cho, Han-Gon, Choi
openaire +2 more sources
Indian drugs, 2017
The objective of the present study was to develop sustained release gastro-retentive (SRGR) tablet formulation of bepotastine besilate for once-a-day dosing using quality by design (QbD) approach.
V. Chudiwal, S. Shahi, S. Chudiwal
semanticscholar +1 more source
The objective of the present study was to develop sustained release gastro-retentive (SRGR) tablet formulation of bepotastine besilate for once-a-day dosing using quality by design (QbD) approach.
V. Chudiwal, S. Shahi, S. Chudiwal
semanticscholar +1 more source
Drug Metabolism and Disposition, 2006
The antiallergic agent bepotastine besilate is a nonsedating, second-generation H1-antagonist with high oral absorption and negligible distribution into brain. To clarify the role of P-glycoprotein (P-gp) in the pharmacokinetics of bepotastine, intestinal absorption and brain penetration studies were performed.
Rikiya, Ohashi +5 more
openaire +2 more sources
The antiallergic agent bepotastine besilate is a nonsedating, second-generation H1-antagonist with high oral absorption and negligible distribution into brain. To clarify the role of P-glycoprotein (P-gp) in the pharmacokinetics of bepotastine, intestinal absorption and brain penetration studies were performed.
Rikiya, Ohashi +5 more
openaire +2 more sources